This human GM-CSF ELISA kit is a 3.5-hour solid phase immunoassay readily applicable to measure GM-CSF in serum, plasma, cell culture supernatant, and other biological fluids in the range of 0 to 500 pg/mL. This human GM-CSF ELISA kit showed no cross reactivity with other cytokines tested. This human GM-CSF ELISA kit applies a technique called a quantitative sandwich immunoassay. Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a member of the hematopoietic cytokine family, which includes interleukin-3 (IL-3) and interleukin-5 (IL-5). It is a pleiotropic cytokine that was one of the first growth factors characterized and shown to be necessary for the proliferation, differentiation, activation, and survival of hematopoietic cells.
In order to measure the concentration of GM-CSF in the samples, this human GM-CSF ELISA kit includes two diluents (Calibrator Diluent I for serum/plasma testing and Calibrator Diluent II for cell culture supernatant testing). According to the testing system, the provided standard is diluted (2-fold dilution series) with the appropriate Calibrator Diluent and assayed at the same time as the samples. This allows the operator to produce a standard curve of Optical Density (O.D.) versus GM-CSF concentration (pg/mL). The concentration of GM-CSF in the samples is then determined by comparing the O.D. of the samples to the standard curve. The minimum detectable dose of GM-CSF using a standard curve generated with Calibrator Diluent I is 1.5-2.0 pg/mL and using Calibrator Diluent II is 2.0 pg/mL. This sandwich human GM-CSF ELISA kit recognizes both natural and recombinant human GM-CSF. This human GM-CSF ELISA kit exhibits no significant cross-reactivity with human; TGF, MCP-1, MCP-3, M-CSF, EGF, IL-1β, IL-8, IL-16, and TNF-α. This human GM-CSF ELISA kit is calibrated against NIBCS/WHO First Standard code No. 88/646.
Human GM-CSF is different from other family members in that it can be produced and act upon a much wider range of cell types. T-lymphocytes, B-lymphocytes, monocytes/macrophages, endothelial cells, fibroblasts, stromal cells, mesothelial cells, keratinocytes, osteoblasts, uterine epithelial cells, synoviocytes, mast cells, and various solid tumours produce GM-CSF. Usually a cytokine, inflammatory agent, or antigen is needed to stimulate the above cells to synthesize GM-CSF.
This human GM-CSF ELISA kit is to be used for the in vitro quantitative determination of human granulocyte macrophage colony stimulating factor (GM-CSF) concentrations in serum, plasma, cell culture supernatant, and other biological fluids. This GM-CSF ELISA kit is expected to be effectively used for further investigations into the relationship between GM-CSF and the various conditions mentioned above. This human GM-CSF ELISA kit is intended for LABORATORY RESEARCH ONLY and is not for use in diagnostic or therapeutic procedures.
Various pathological conditions are associated with increased GM-CSF levels. These include: lung cancer, acute mylogenous leukemia, tumour related thrombocytosis, myelodysplastic syndrome (MDS), thrombocytopenia, and psoriasis. GM-CSF expression is increased in bronchial asthma and lung inflammatory diseases; non-allergic respiratory diseases such as eosinophil pneumonia, hypersensitivity pneumonitis, iodiopathic pulmonary fibrosis, sarcoidosis, cryptogenic organizing pneumonia, HIV infection, rheumatoid arthritis, and systemic lupus erythmatosus. GM-CSF shows therapeutic value by accelerating neutrophil recovery in disease induced myelosuppression such as bone marrow transplantation, chemotherapy, and infectious disease. It is suggested that a GM-CSF may be useful in autologous bone marrow transplantation to detect GM-CSF toxicity for the diagnosis of post-transplant liver disease and in gestational trophoblastic disease (GTD) for the early identification of high risk choriocarcinoma cases.
Download Product Data Sheet